| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10919187 | Radiotherapy and Oncology | 2013 | 7 Pages |
Abstract
PBT is an option for treating recurrent NSCLC. However, the rates of locoregional recurrence and distant metastasis are high and the potential for toxicity significant. The risks and benefits of PBT must be carefully weighed in each case.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Sarah A. McAvoy, Katherine T. Ciura, Justin M. Rineer, Pamela K. Allen, Zhongxing Liao, Joe Y. Chang, Matthew B. Palmer, James D. Cox, Ritsuko Komaki, Daniel R. Gomez,